Rapid detection of major depression in epilepsy: a multicentre study

Gilliam, Frank; Barry, John J.; Hermann, Bruce P.; Meador, Kimford J.; Vahle, Victoria; Kanner, Andrés M.

doi:10.1016/s1474-4422(06)70415-x

Cited by 551 publications

(411 citation statements)

References 41 publications

Supporting

Mentioning

366

Contrasting

Unclassified

Order By: Relevance

“…sensitivity and a predictive value of 0.62 for a diagnosis of major depression [23] and NDDI-E was also found to have significant positive correlation with another screening tool for depression, the Patient Health Questionnaire [24].…”

Section: Neurological Disorders Depression Inventory For Epilepsy (Ndmentioning

confidence: 83%

“…Higher scores on the NDDI-E indicate greater impairment. The inventory was found to have good internal consistency and test-retest reliability [23,24]. A score of more than 15 on the NDDI-E was found to have 90% specificity, 81%…”

Section: Neurological Disorders Depression Inventory For Epilepsy (Ndmentioning

confidence: 94%

“…The six items represent common symptoms of depression experienced in the past two weeks that can be differentiated from adverse effects of anti-epileptic drugs [23]. Higher scores on the NDDI-E indicate greater impairment.…”

Section: Neurological Disorders Depression Inventory For Epilepsy (Ndmentioning

confidence: 99%

See 2 more Smart Citations

A prospective service evaluation of acceptance and commitment therapy for patients with refractory epilepsy

Dewhurst

Nováková

Reuber

2015

Epilepsy & Behavior

View full text Add to dashboard Cite

Objective: The aim of this service evaluation was to explore the effectiveness of a psychotherapeutic treatment for patients with epilepsy based on the Acceptance and Commitment Therapy (ACT) approach and to assess whether this treatment is likely to be cost-effective. Method:We conducted an uncontrolled prospective study of consecutive patients with refractory epilepsy referred for outpatient psychological treatment to a single psychotherapist because of emotional difficulties related to their seizure disorder. Participants were referred by consultant neurologists, neuropsychologists or epilepsy nurses and completed a set of validated self-report questionnaires (Short Form -12 Version 2, Generalised Anxiety Disorder -7, Neurological Disorders Depression Inventory for Epilepsy, Work and Social Adjustment Scale, and Rosenberg Self-Esteem Scale) at referral, the end of therapy and six months post therapy. Patients received a maximum of 20 sessions of one-to-one psychological treatment supported by a workbook. Cost-effectiveness was estimated based on the calculation of quality-adjusted life year (QALY) gains associated with the intervention.Results: Sixty patients completed the pre-and post-psychotherapy questionnaires, 41 also provided six-month follow-up data. Patients received six to 20 sessions of psychotherapy (mean = 11.5, S.D. = 9.6). Psychotherapy was associated with significant medium to large positive effects on depression, anxiety, quality of life, self-esteem, work and social adjustment (Ps < .001), which were sustained six months after therapy. The mean cost of the psychotherapy was £445.6 and, assuming that benefits were maintained for at least six months after the end of therapy, the cost per QALY was estimated to be £11,140 ( 9, $18,016; the cost per QALY would be half this amount if the benefits lasted one year). Conclusion:The findings of this pilot study indicate that the described psychotherapeutic intervention may be a cost-effective treatment for patients with epilepsy. The results suggest that randomised controlled trial of the psychotherapy programme is justified.

show abstract

Section: Neurological Disorders Depression Inventory For Epilepsy (Ndmentioning

confidence: 83%

Section: Neurological Disorders Depression Inventory For Epilepsy (Ndmentioning

confidence: 94%

See 1 more Smart Citation

A prospective service evaluation of acceptance and commitment therapy for patients with refractory epilepsy

Dewhurst

Nováková

Reuber

2015

Epilepsy & Behavior

View full text Add to dashboard Cite

show abstract

“…As for depression, a first step achieving this in epilepsy must surely be to ensure those who might benefit are more easily identified when attending epilepsy outpatients" clinics. A range of tools have been developed and validated for detection of depression in PwE by ourselves and others 14,15 . In the present paper we investigate whether a range of traditional and visual analogue depression screening tools are also effective in detecting anxiety disorders.…”

Section: Introductionmentioning

confidence: 99%

Screening of anxiety and quality of life in people with epilepsy

Özmen

Leibetseder

Cock

et al. 2017

Seizure

View full text Add to dashboard Cite

PURPOSEUp to 60% of people with epilepsy (PwE) have psychiatric comorbidity including anxiety.Anxiety remains under recognized in PwE. This study investigates if screening tools validated for depression could be used to detect anxiety disorders in PWE. Additionally it analyses the effect of anxiety on QoL. METHODS261 participants with a confirmed diagnosis of epilepsy were included. Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) and Emotional Thermometers (ET), both validated to screen for depression were used. Hospital Anxiety and Depression ScaleAnxiety (HADS-A) with a cut off for moderate and severe anxiety was used as the reference standard. QoL was measured with EQ5-D. Sensitivity, specificity, positive and negative predictive value and ROC analysis as well as multivariate regression analysis were performed. RESULTSPatients with depression (n=46) were excluded as multivariate regression analysis showed that depression was the only significant determinant of having anxiety in the group. Against HADS-A, NDDI-E and ET-7 showed highest level of accuracy in recognizing anxiety with ET7 being the most effective tool. QoL was significantly reduced in PwE and anxiety. CONCLUSIONSOur study showed that reliable screening for moderate to severe anxiety in PwE without comorbid depression is feasible with screening tools for depression. The cut off values for anxiety are different from those for depression in ET7 but very similar in NDDI-E. ET7 can be applied to screen simultaneously for depression and "pure" anxiety. Anxiety reduces significantly QoL. We recommend screening as an initial first step to rule out patients who are unlikely to have anxiety.Highlights  Moderate to severe anxiety is a frequent comorbidity in epilepsy, in our cohort prevalence was 26,4%  Depression was the only significant determinant for anxiety, prevalence of anxiety in non-depressed PwE was 15,8%. Screening for anxiety independent from depression can be achieved with the ET7 tool.

show abstract

“…I tillegg til et målrettet klinisk intervju kan symptomer på depresjon fanges opp ved bruk av enkle spørreskjemaer som Becks Depression Inventory (BDI) (36), Hospital Anxiety and Depression Scale (HADS) (37), Montgomery and Aasberg Depression Rating Scale (MADRS) (38) eller Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) (39). Etter vår erfaring er NDDI-E best egnet til rask screening i en travel klinisk hverdag.…”

Section: Diagnostikkunclassified

Epilepsi og depresjon

Henning¹,

Nakken²

2011

Tidsskriftet

View full text Add to dashboard Cite

Rapid detection of major depression in epilepsy: a multicentre study

Cited by 551 publications

References 41 publications

A prospective service evaluation of acceptance and commitment therapy for patients with refractory epilepsy

A prospective service evaluation of acceptance and commitment therapy for patients with refractory epilepsy

Screening of anxiety and quality of life in people with epilepsy

Epilepsi og depresjon

Contact Info

Product

Resources

About